Canaccord Genuity analyst Mark Massaro reiterated a Buy rating on HTG Molecular Diagnostics (NASDAQ: HTGM) yesterday and set a price target of $6. The company’s shares closed yesterday at $3.30.
According to TipRanks.com, Massaro is a 5-star analyst with an average return of 17.4% and a 62.2% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Idexx Laboratories, Exact Sciences, and Genomic Health.
Currently, the analyst consensus on HTG Molecular Diagnostics is a Moderate Buy with an average price target of $6.50, which is a 97.0% upside from current levels. In a report issued on August 8, H.C. Wainwright also reiterated a Buy rating on the stock with a $7 price target.
.
See today’s analyst top recommended stocks >>
Based on HTG Molecular Diagnostics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $4.1 million. In comparison, last year the company had a GAAP net loss of $5.84 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. Its customers include biopharmaceutical companies, academic research centers, and molecular testing laboratories. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.
